Related Experiment Video
Updated: Jul 10, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
Update on new antifungal therapy
1Department of Pharmacy Practice, St Louis College of Pharmacy, 4588 Parkview Place, St Louis, MO 63110, USA. pjuang@stlcop.edu
Abstract:
Increases in rates as well as morbidity and mortality associated with fungal infections have necessitated the need for additional antifungal agents. Recent research has resulted in the introduction of 3 new antifungal agents: micafungin, anidulafungin, and posaconazole. Micafungin and anidulafungin, both potent inhibitor of 1,3-beta-D-glucan synthase, are the second and third available agents in the echinocandins class that are available in clinical practice. Posaconazale, a potent inhibitor of ergosterol synthesis, is a new agent in the triazole class that has shown promising clinical efficacy in the treatment and prophylaxis of invasive fungal infections due to Candida as well as molds. This article reviews the clinical efficacy as well as the approved uses and dosages associated with the use of these new antifungal agents. Other considerations, such as precautions, administration techniques, potential drug interactions, and common adverse effects associated with the use of these agents, are also reviewed.
Insights
New antifungal agents, micafungin, anidulafungin, and posaconazole, offer improved treatment options for invasive fungal infections. This review details their efficacy, usage, and safety profiles for clinicians.
Area of Science:
- Infectious Diseases
- Pharmacology
- Mycology
Background:
- Rising rates of fungal infections, morbidity, and mortality necessitate novel antifungal therapies.
- Echinocandins and triazoles represent key classes of antifungal medications.
Purpose of the Study:
- To review the clinical efficacy of three new antifungal agents: micafungin, anidulafungin, and posaconazole.
- To outline approved uses, dosages, and administration guidelines for these agents.
Main Methods:
- Review of clinical efficacy data for micafungin, anidulafungin, and posaconazole.
- Analysis of approved indications, dosing regimens, and administration techniques.
- Evaluation of drug interactions, precautions, and adverse effects.
Main Results:
- Micafungin and anidulafungin are echinocandins inhibiting 1,3-beta-D-glucan synthase.
- Posaconazole is a triazole inhibiting ergosterol synthesis, effective against Candida and molds.
- These agents demonstrate promising efficacy in treating and preventing invasive fungal infections.
Conclusions:
- Micafungin, anidulafungin, and posaconazole represent significant advancements in antifungal treatment.
- Understanding their specific mechanisms, efficacy, and safety is crucial for optimal patient care.
Related Concept Videos
Antifungal Agents
Antiprotozoal Agents
Cryptococcal Meningitis
Candidiasis
Drug Therapy
Antianxiety Medications
Antimicrobial Effectiveness
